rolipram has been researched along with Weight Gain in 7 studies
Weight Gain: Increase in BODY WEIGHT over existing weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to evaluate the efficacy of rolipram, a phosphodiesterase (PDE) 4 inhibitor, in a mouse model of dermatitis induced by repeated application of 2,4,6-trinitro-1-chlorobenzene (TNCB)." | 7.73 | Effect of orally administered rolipram, a phosphodiesterase 4 inhibitor, on a mouse model of the dermatitis caused by 2,4,6-trinitro-1-chlorobenzene (TNCB)-repeated application. ( Harada, D; Manabe, H; Takashima, Y; Tsukumo, Y, 2006) |
| "Obesity is a major health problem." | 5.40 | The effects of forskolin and rolipram on cAMP, cGMP and free fatty acid levels in diet induced obesity. ( Doseyici, S; Erbay, E; Mehmetoglu, I; Toker, A; Yerlikaya, FH, 2014) |
| "Rat pups were placed under hyperoxia (FiO2>95%) or room air from birth, and received rolipram or its diluent daily until sacrifice." | 3.74 | Effects of phosphodiesterase 4 inhibition on alveolarization and hyperoxia toxicity in newborn rats. ( Boucherat, O; Bourbon, J; Delacourt, C; Evain-Brion, D; Franco-Montoya, ML; Jarreau, PH; Lopez, E; Méhats, C; Schmitz, T; Zana, E, 2008) |
| "The purpose of this study was to evaluate the efficacy of rolipram, a phosphodiesterase (PDE) 4 inhibitor, in a mouse model of dermatitis induced by repeated application of 2,4,6-trinitro-1-chlorobenzene (TNCB)." | 3.73 | Effect of orally administered rolipram, a phosphodiesterase 4 inhibitor, on a mouse model of the dermatitis caused by 2,4,6-trinitro-1-chlorobenzene (TNCB)-repeated application. ( Harada, D; Manabe, H; Takashima, Y; Tsukumo, Y, 2006) |
| "Obesity is a major health problem." | 1.40 | The effects of forskolin and rolipram on cAMP, cGMP and free fatty acid levels in diet induced obesity. ( Doseyici, S; Erbay, E; Mehmetoglu, I; Toker, A; Yerlikaya, FH, 2014) |
| "Chorioamnionitis is implicated in the pathophysiology of bronchopulmonary disease, and the associated inflammatory response is responsible for adverse effects on alveolar development." | 1.38 | Antenatal phosphodiesterase 4 inhibition restores postnatal growth and pulmonary development in a model of chorioamnionitis in rabbits. ( Branger, B; Caillon, J; Gras-Leguen, C; Homer, L; Jacqueline, C; Jarreau, PH; Joram, N; Launay, E; Méhats, C; Moyon, T; Potel, G; Roze, JC, 2012) |
| "Rolipram is a selective inhibitor of Type IV phosphodiesterase isozymes (PDE IV) which is often used as a baseline comparator for compounds in this class." | 1.29 | The toxicity of repeated exposures to rolipram, a type IV phosphodiesterase inhibitor, in rats. ( Geiger, LE; Larson, JL; Pino, MV; Simeone, CR, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Doseyici, S | 1 |
| Mehmetoglu, I | 1 |
| Toker, A | 1 |
| Yerlikaya, FH | 1 |
| Erbay, E | 1 |
| Méhats, C | 2 |
| Franco-Montoya, ML | 1 |
| Boucherat, O | 1 |
| Lopez, E | 1 |
| Schmitz, T | 1 |
| Zana, E | 1 |
| Evain-Brion, D | 1 |
| Bourbon, J | 1 |
| Delacourt, C | 1 |
| Jarreau, PH | 2 |
| Homer, L | 1 |
| Launay, E | 1 |
| Joram, N | 1 |
| Jacqueline, C | 1 |
| Caillon, J | 1 |
| Moyon, T | 1 |
| Branger, B | 1 |
| Potel, G | 1 |
| Roze, JC | 1 |
| Gras-Leguen, C | 1 |
| Schütte, H | 1 |
| Schell, A | 1 |
| Schäfer, C | 1 |
| Ghofrani, A | 1 |
| Theo Schermuly, R | 1 |
| Seeger, W | 1 |
| Grimminger, F | 1 |
| Harada, D | 1 |
| Tsukumo, Y | 1 |
| Takashima, Y | 1 |
| Manabe, H | 1 |
| Larson, JL | 1 |
| Pino, MV | 1 |
| Geiger, LE | 1 |
| Simeone, CR | 1 |
| Overstreet, DH | 1 |
| Double, K | 1 |
| Schiller, GD | 1 |
7 other studies available for rolipram and Weight Gain
| Article | Year |
|---|---|
The effects of forskolin and rolipram on cAMP, cGMP and free fatty acid levels in diet induced obesity.
Topics: Animals; Colforsin; Cyclic AMP; Cyclic GMP; Diet, High-Fat; Fatty Acids, Nonesterified; Female; Lipo | 2014 |
Effects of phosphodiesterase 4 inhibition on alveolarization and hyperoxia toxicity in newborn rats.
Topics: Animals; Animals, Newborn; Hyperoxia; Inflammation; Lung Injury; Phosphodiesterase 4 Inhibitors; Pho | 2008 |
Antenatal phosphodiesterase 4 inhibition restores postnatal growth and pulmonary development in a model of chorioamnionitis in rabbits.
Topics: Animals; Chorioamnionitis; Disease Models, Animal; Elastic Tissue; Female; Lung; Lung Volume Measure | 2012 |
Subthreshold doses of nebulized prostacyclin and rolipram synergistaically protect against lung ischemia-reperfusion.
Topics: Animals; Capillary Permeability; Cyclic AMP; Disease Models, Animal; Drug Synergism; Epoprostenol; F | 2003 |
Effect of orally administered rolipram, a phosphodiesterase 4 inhibitor, on a mouse model of the dermatitis caused by 2,4,6-trinitro-1-chlorobenzene (TNCB)-repeated application.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Oral; Animals; Anti-Inflammatory Agents; Cell C | 2006 |
The toxicity of repeated exposures to rolipram, a type IV phosphodiesterase inhibitor, in rats.
Topics: Animals; Blood Vessels; Body Weight; Eating; Female; Liver; Myocardium; Necrosis; Organ Size; Phosph | 1996 |
Antidepressant effects of rolipram in a genetic animal model of depression: cholinergic supersensitivity and weight gain.
Topics: Albuterol; Animals; Antidepressive Agents; Avoidance Learning; Body Temperature; Brain; Depressive D | 1989 |